JPMORGAN US SMALLER COMPANIES INVESTMENT TRUST PLC
The next big thing starts small
The JPMorgan US Smaller Companies Investment Trust plc uses the stock-picking credentials of our US based investment team to invest in well-run companies with attractive and sustainable profits from the potentially faster growing smaller companies segment of the US stock market.
Why invest in the US?
Fiona Harris, Client Portfolio Manager, discusses the opportunities and challenges of investing in the US market.
Some of the themes discussed include:
- What to consider when thinking about investing in the US
- How the evolution of technology is opening investment opportunities
- Myth busting investing in the US
About this trust
- Managed by locally based specialist investors, focused on finding the small cap opportunities within North America
- Seeks well-run US smaller companies with a sustainable competitive advantage, that have a record of success and are good stewards of capital
- Provides access to some of the world’s fastest growing smaller companies in an under researched market
Investment objective and policies
The Company aims to provide investors with capital growth by investing in US smaller companies that have a sustainable competitive advantage and to focus on owning equity stakes in businesses that trade at a discount to their intrinsic value, with strong management teams. The company has the ability to use borrowing to gear the portfolio to up to 15% of net assets where appropriate.
Points to consider
- The value of investments and the income from them can go down and up, and you may not get back as much as you paid in. Past performance is not a guide to the future.
- Exchange rate changes may cause the value of underlying overseas investments to go down as well as up.
- Investments in smaller companies may involve a higher degree of risk as these are usually more sensitive to price movements.
- External factors may cause an entire asset class to decline in value. Prices and values of all shares or all bonds could decline at the same time.
- This trust may utlilise gearing (borrowing) which will exaggerate market movements both up and down.
Board of Directors
In their words (as of 28 Feb 2018)
On the other hand, our stock selection in the healthcare and consumer staples sectors hurt performance, with West Pharmaceutical emerging as the biggest detractor within the healthcare space. At the security level, our exposure to Spectrum Brands was the largest detractor within consumer staples after it reported quarterly earnings that missed estimates.
Committee Terms Of Reference
Reports and Accounts
- 2017 Half Year Report
- 2016 Annual Report
- 2016 Half Year Report
- 2015 Annual Report
- 2015 Half Year Report
- 2014 Annual Report
- 2014 Half Year Report
- 2013 Annual Report
- 2013 Half Year Report
- 2012 Annual Report
- 2012 Half Year Report
- 2011 Annual Report
- 2011 Half Year Report
- 2010 Annual Report
- 2010 Half Year Report
- 2009 Annual Report
- 2009 Half Year Report
How to buy this trust
Buy from a third party provider
J.P. Morgan investment trusts and funds are available via a range of third party providers.
Third party providers
Buy from a professional adviser
Professional advisers are usually able to access the products of all the companies in the market and can help you find an investment that suits your individual circumstances. A financial adviser will let you know the fee for their service before you go ahead.
Find out more
For contact details and more information on our trust range use the following links:
This is a promotional page and as such the views contained herein are not to be taken as advice or recommendation to buy or sell any investment or interest thereto. Reliance upon information in this material is at the sole discretion of the reader. Any research on this page has been obtained and may have been acted upon by J.P. Morgan Asset Management for its own purpose. The results of such research are being made available as additional information and do not necessarily reflect the views of J.P. Morgan Asset Management. Any forecasts, figures, opinions, statements of financial market trends or investment techniques and strategies expressed are unless otherwise stated, J.P. Morgan Asset Management’s at the date of publishing. They are considered to be reliable at the time of publishing, may not necessarily be all-inclusive and are not guaranteed as to accuracy. They may be subject to change without reference or notification to you.
It should be noted that the value of investments and the income from them may fluctuate in accordance with market conditions and taxation agreements and investors may not get back the full amount invested. Changes in exchange rates may have an adverse effect on the value, price or income of the products or underlying overseas investments. Past performance is not a reliable indicator to current and future results. There is no guarantee that any forecast made will come to pass. Furthermore, whilst it is the intention to achieve the investment objective of the investment products, there can be no assurance that those objectives will be met.
Investment is subject to documentation (Investor Disclosure Document, Key Features and Terms and Conditions), copies of which can be obtained free of charge from JPMorgan Asset Management Marketing Limited. Issued by JPMorgan Asset Management Marketing Limited which is authorised and regulated in the UK by the Financial Conduct Authority. Registered in England No: 288553. Registered address: 25 Bank St, Canary Wharf, London E14 5JP.
*Morningstar Analyst rating and FE Crown rating as at 01 February 2018.
Source: Morningstar (www.morningstar.co.uk)
Morningstar Ratings™: © 2017 Morningstar. All rights reserved.
FE Crown Fund Ratings © 2017 FE. All rights reserved.
Moneyfacts award as at: 17 October 2017. ©2017 Moneyfacts Group plc. All Rights Reserved.
© 2017 citywire.co.uk. All Rights Reserved.